A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
Two masked bispecific antibodies, licensed for $100m, produce promising early data.
Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.
The private group taps DualityBio for an EGFR x HER3 ADC.
The fate of the group’s previous lead project, the Amgen-partnered CX-904, looks uncertain.
Olema will soon enter the clinic, and Pfizer could shortly be in phase 3.
A new phase 3 study will test Anktiva in PD-(L)1-relapsed lung cancer.
